Clomipramine Hydrochloride (Prolonged Release)Third Party Manufacturing in India

Clomipramine Hydrochloride works primarily by potently inhibiting the reuptake of serotonin and, to a lesser extent, norepinephrine at the presynaptic neuronal membrane. By blocking serotonin transporters, it increases the availability of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission. This mechanism underpins its particular efficacy in obsessive-compulsive disorder where serotonergic dysregulation plays a central role.

With chronic administration, clomipramine downregulates cerebral cortical beta-adrenergic receptors and sensitizes postsynaptic serotonergic receptors, contributing to its delayed therapeutic onset. The drug undergoes hepatic demethylation via CYP2D6 and CYP2C19 to its primary active metabolite, desmethylclomipramine, which additionally inhibits norepinephrine reuptake and broadens the pharmacological effect. Clomipramine also antagonizes histamine H1 receptors, muscarinic acetylcholine receptors, and alpha-1 adrenergic receptors, accounting for its sedative, anticholinergic, and hypotensive side effect profile.

The prolonged release formulation maintains more stable plasma concentrations over 24 hours, reducing peak-related side effects and allowing once-daily dosing. This improves patient compliance while delivering equivalent therapeutic efficacy to the immediate-release form.

Clomipramine Hydrochloride is a tricyclic antidepressant indicated primarily for obsessive-compulsive disorder and related conditions. The prolonged release formulation offers the advantage of once-daily dosing.

Therapeutic Uses

• Obsessive-Compulsive Disorder: The primary indication, where clomipramine reduces the frequency and intensity of obsessions and compulsions through potent serotonin reuptake inhibition.
• Major Depressive Disorder: Effective for depression, particularly when accompanied by obsessive features, anxiety, or poor response to SSRIs.
• Panic Disorder: Used for panic symptoms with or without agoraphobia, especially in treatment-resistant cases.
• Chronic Pain Syndromes: Prescribed off-label for neuropathic pain, tension headaches, and diabetic peripheral neuropathy.
• Cataplexy with Narcolepsy: Helps manage cataplexy episodes through its REM-suppressant properties.

Why Manufacturers Choose Clomipramine Hydrochloride

Clomipramine Hydrochloride maintains a stable position in the Indian psychiatric pharmaceutical market despite competition from newer SSRIs. The prolonged release 75mg tablet offers a differentiated product that addresses an unmet need for patients requiring once-daily dosing with fewer side effects. Indian WHO-GMP certified manufacturers supply clomipramine to both domestic and export markets, with particular demand from price-sensitive healthcare systems in Asia and Africa where cost-effective tricyclic antidepressants remain first-line therapy. The prolonged release formulation allows manufacturers to offer value-added products with better compliance profiles, commanding premium pricing over standard immediate-release tablets. This makes Clomipramine Hydrochloride prolonged release an attractive molecule for PCD franchise partners seeking to differentiate their psychiatric portfolio.